However, few studies have investigated whether replacing insulin therapy with a combination of a GLP-1 receptor agonist and OHAs could be effective in patients with uncontrolled T2D receiving insulin therapy. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.